High-affinity GHS-R1a agonist with greater intrinsic efficacy than GHRP-2 or GHRP-6. Unique: direct cardioprotective mechanism via CD36 scavenger receptor activation independent of GH axis. Anti-apoptotic in cardiac myocytes. Some evidence of GH receptor desensitization with continuous use.
Studies have administered: 1–2mcg/kg per injection; 200mcg maximum typical dose in research; cycling recommended
Most potent GH releaser in GHRP class. Cardiac: Dickson (2001) demonstrated cardioprotection in MI models independent of GH. IGF-1 elevation sustained. Desensitization well-documented — necessitates intermittent cycling.
Greater cortisol, prolactin co-stimulation than ipamorelin; tachyphylaxis with continuous use; water retention; hyperprolactinemia risk with long-term use
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on Hexarelin — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat